Funding

PART B: VALORISATION PLAN

SECTION I: ESTIMATION OF COSTS

 

1 Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
In this section we expect an analysis of funding needed or expected for valorization of the R&D result. An estimation is expected (range of costs not obviously exact amounts)
… in terms of IPR protection
A software can’t be protected by a patent. 

Within European Union member states, indeed, a computer-implemented inventions which only solve a business problem using a computer, rather than a technical problem, are considered unpatentable as lacking an inventive step.

Software is protected as works of literature under the Berne Convention. This allows the creator to prevent another entity from copying the program and there is generally no need to register code in order for it to be copyrighted.

So, in this case the protection does not provide significant costs.

 

…in terms of product development
 

In terms of product development, CRO needs a software developer (35.000 €).

Moreover CRO has to consider the certification costs, that are not quantifiable at the moment.

 

 

 

…in terms of mass production
 

There are not specific mass production costs

 

 

… in terms of marketing
 

miCRO will be promoted via web, so the marketing costs will be very low.

 

 

 

2 Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs
Year 1 Year 2 Year 3 Year 4 Year 5
Fixed costs 5.000 5.000 5.000 5.000 5.000
Personnel 35.000 35.000 45.000 70.000 70.000
Other running costs 3.500 6.000 10.000 15.000 20.000
Marketing costs 5.000 5.000 5.000 5.000 5.000
TOTAL EXPECTED COSTS 48.500 51.000 65.000 95.000 100.000
Price per Unit 1.000 1.000 1.000 1.000 1.000
Type of Unit
Number of Units 35 60 100 150 200
TOTAL Expected Revenues 35.000 60.000 100.000 150.000 200.000
CASH FLOW REQUIRED (REVENUES-COSTS) (13.500) 9.000 35.000 55.000 100.000
TOTAL CAPITAL required for five years 13.500

 

SECTION 2: QUALITATIVE FACTORS

 

4 Dimension of identified target groups
An estimation of the proportion of the target market (described in Section 3) which we expect to take
 

In Italy: there are 33 excellence hospitals for chemotherapy and other medical therapies, but there are more than 150 hospitals with an oncology unit

So we can estimate a market of about 200 users in Italy

From this starting point, we can estimate more than 150.000 units all around the world.

A cautious target market can be 1.500 unit (that is 1% of 150.000)

 

 

 

 

 

6 Evaluation of financial Risks for R&D result
 

The project has no particular financial risks, because it doesn’t need any investment in fixed assets.

 

 

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

1. European Funding 

Define relevance of the product with the following potential funding sources and comment

Note: INTERVALUE partners are expected to pre-define a list of existing European funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. …FP7 

2. …FP8

3.

4.

2 National Funding
Note: INTERVALUE partners are expected to pre-define a list of existing national funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. … LR 4/2005 (Friuli Venezia Giulia regional law for the development of innovative projects whose objective is the company growth) 

2. …LR 26/2005 (Friuli Venezia Giulia regional law on innovation)

3.

4.

3 Private funding
Note: INTERVALUE partners are expected to pre-define a list of existing private funding sources for product development available for the country and advisors will check whether the proposed product is relevant for that funding source or may define an additional source
1. …Business Angel/Venture capitalist 

2.

3.

4 Other

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
CRO is one of the most important National Cancer Institutes. 

CRO should invest in the miCRO software project in order think about the opportunity of a partnership with a company that produces cancer treatment infrastructures.

It should be strategic indeed to sell the software via web and to propone a demo within the CRO website.

 

 

 

 

 

 

 

Decision of evaluation (Please tick  as appropriate)

þ The R&D has a high potential of exploitation
The R&D result needs minor revisions
The R&D result needs moderate revisions
The R&D result needs major revisions
The R&D result has no potential of exploitation

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project